CTOs on the Move


 
Afaxys mission is to deliver products and services to public health providers affordably, reliably and with an unwavering focus on customer service.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.afaxys.com
  • 455 1/2, King St
    Charleston, SC USA 29403
  • Phone: 855.888.2467

Executives

Name Title Contact Details

Similar Companies

Laboratoires Vivacy

Hyaluronic Acid Experts - Aesthetics Medecine – Dermo Cosmetic - Intimate Care

Astellas

Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In 2005, Astellas was formed by blending the talents, resources and passions of two highly successful firms - Yamanouchi and Fujisawa. Astellas aims to maintain and strengthen our position as the global leader in transplantation and urology areas, and going forward we are working to establish our position as a global category leader in oncology. At all levels throughout the company our people are committed to the opportunity to positively affect and improve patient lives while remaining socially responsible to our community and those with whom we work and collaborate.

P.E.C.S.

P.E.C.S. is a Canovanas, PR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zentaris

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company`s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.

RW Troxell

RW Troxell is a Springfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.